ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1409

Increase in the Use of Validated Disease Activity Scores in Current Daily Clinical Practice Compared to 2007

Marieke J. de Jonge1, Laura W.M. Boerboom1, Anita M.P. Huis1, Julia M. Weijers1, Mart A.F.J. van de Laar2, Marlies E.J.L. Hulscher1 and Piet L.C.M. van Riel1,3, 1Radboud university medical center, Radboud Institute for Health Sciences, IQ healthcare, Nijmegen, Netherlands, 2University of Twente, Department of Psychology, Health and Technology, Enschede, Netherlands, 3Bernhoven, Department of Rheumatology, Uden, Netherlands

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Clinical practice, Disease Activity, Guidelines and quality

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Quality Measures and Quality of Care - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: International guidelines and studies recommend rheumatologists to use validated measures to monitor disease activity, such as the Disease Activity Score of 28 joints (DAS28). However, based on previous research, that recommendation was marginally followed in daily clinical practice. Before the dissemination of the Dutch guideline, it was found that in 16% of the patient’s visits a measure for disease activity was obtained.[1] Up till now it is unknown whether adherence to tight control increased since the dissemination of the Dutch guideline in 2009. This study aims to evaluate whether the use of validated disease activity scores has changed since 2007.

Methods: To increase the precision of the study, Dutch rheumatologists that participated in the study of 2007 were invited to re-enter the study, If necessary, data were supplemented with data from colleagues and ‘new’ rheumatologists. Per rheumatologist, data was collected from the first 30 consecutive patients that visited the outpatient clinic. Per patient, data from four consecutive rheumatologist visits were collected. Data were collected by local nurses or by a research assistant, using case record forms. Disease activity was considered to be measured when either a validated score was reported in patients’ medical chart, or when the researchers could calculate a validated score from the reported data (see figure 1). To allow comparison, this definition is the same as van Hulst et al. used in their 2007 measurement.[1]

Results: At this phase of the study, a medical chart review was performed on a sample of 1044 visits, within 10 rheumatologists, within 7 Dutch rheumatology outpatient clinics. These preliminary results show that in 84.0% (877/1044) of the visits a RA disease activity score was reported. Of those visits, a DAS28 score was reported in 49.6%(435/877) of the cases, a DAS28-CRP score was reported in 13.5% (118/877) of the cases, and a DAS score was reported in 2.6% (23/877) of the cases. In the remaining 34.3% (301/877) of the cases, another disease activity score was used (see figure 1).

Conclusion: Based on the preliminary results, the use of validated disease activity scores has increased since 2007. Currently, a medical chart review on a sample of 35 Dutch rheumatologists is still ongoing. Ultimately, we will present data on their use of validated disease activity scores, as well as on medication regimen changes based on disease activity.   References: 1. van Hulst LT, Hulscher ME, van Riel PL. Achieving tight control in rheumatoid arthritis. Rheumatology (Oxford, England). 2011;50(10):1729-31.   Acknowledgements: We thank all participating rheumatologist and nurses for their cooperation.    

             


Disclosure: M. J. de Jonge, None; L. W. M. Boerboom, None; A. M. P. Huis, None; J. M. Weijers, None; M. A. F. J. van de Laar, None; M. E. J. L. Hulscher, None; P. L. C. M. van Riel, None.

To cite this abstract in AMA style:

de Jonge MJ, Boerboom LWM, Huis AMP, Weijers JM, van de Laar MAFJ, Hulscher MEJL, van Riel PLCM. Increase in the Use of Validated Disease Activity Scores in Current Daily Clinical Practice Compared to 2007 [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/increase-in-the-use-of-validated-disease-activity-scores-in-current-daily-clinical-practice-compared-to-2007/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increase-in-the-use-of-validated-disease-activity-scores-in-current-daily-clinical-practice-compared-to-2007/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology